Lupin, a global pharmaceutical company headquartered in Mumbai, India, has entered into a strategic partnership with SUP, a Chinese pharmaceutical firm, to introduce Tiotropium Dry Powder Inhaler (DPI) in China. Under the agreement, SUP will be responsible for obtaining the necessary regulatory approvals for the product in China, while Lupin will serve as the marketing authorization holder and oversee its manufacturing.
Tiotropium DPI is a widely used therapy for managing chronic respiratory conditions, notably chronic obstructive pulmonary disease (COPD). Known for its ability to improve lung function and enhance quality of life, it is considered a critical medication in the treatment of respiratory diseases. With respiratory illnesses on the rise in China, this partnership aims to address growing patient needs by ensuring timely access to high-quality, innovative treatment options.
Fabrice Egros, President of Corporate Development at Lupin, expressed confidence in the collaboration, stating, “We are very pleased to partner with SUP to bring Tiotropium DPI to patients in China. This partnership demonstrates our commitment to developing critical products for respiratory care and establishing our leadership in the global respiratory health sector. SUP is our esteemed partner, and together we aim to enhance patient access to high-quality healthcare solutions.”
Wang Li, President of SUP, echoed the sentiment, highlighting the synergy between the two companies. “We are truly honored to partner with Lupin, a global pharmaceutical leader. Lupin’s strong focus on respiratory disease treatment and its innovation-driven approach align perfectly with SUP’s vision. We believe this collaboration will enable significant advancements in respiratory care in China, allowing more patients to benefit from international standards in treatment.”
Lupin’s presence spans over 100 global markets, offering a broad portfolio that includes branded and generic pharmaceuticals, complex generics, biosimilars, and active pharmaceutical ingredients. This partnership with SUP marks a strategic step forward in Lupin’s goal to expand its footprint in Asia and further strengthen its position in the respiratory segment.